Human immunodeficiency virus type 1 groups N, O and P variants;Les variants des groupes N, O et P du virus de l'immunodéficience humaine de type 1

Virologie

Volumn 14, Issue 5, 2010, Pages 334-348

  Vessière, Aurélia ^a   Simon, François ^b   Plantier, Jean Christophe ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Genetic diversity; Group N; Group O; Group P; HIV 1; SIV

Indexed keywords

CAMEROON; CENTRAL AFRICA; CHIMPANZEE; DIFFUSION; EPIDEMIC; EVOLUTION; FRANCE; GENETIC VARIABILITY; GENOMICS; GORILLA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 M; HUMAN IMMUNODEFICIENCY VIRUS 1 N; HUMAN IMMUNODEFICIENCY VIRUS 1 O; HUMAN IMMUNODEFICIENCY VIRUS 1 P; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; REVIEW; SEROLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; PAN; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 78149375894     PISSN: 12678694     EISSN: 19506961     Source Type: Journal    
DOI: 10.1684/vir.2010.0318     Document Type: Review

References (81)

1. Barré-Sinoussi F, Chermann JC, Rey P, et al. Isolation of a T-Lymphotropic Retrovirus from a patient at risk for Acquired Immune Deficiency Syndrome (AlDS). Science 1983 ; 220 : 868-71.
2. Barin F, M'Boup S, Denis F, et al. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa. Lancet 1985 ; 2 : 1387-9. (Pubitemid 16138553)
3. Clavel F, Guétard D, Brun-Vézinet F, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986 ; 233 : 343-6.
4. De Leys R, Vanderborght B, Vanden Haesevelde M, et al. Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of West-Central African origin. J Virol 1990 ; 64 : 1207-16.
5. Nkengasong JN, Peeters M, vanden Haesevelde M, et al. Antigenic evidence of the presence of the aberrant HIV-1ant70 virus in Cameroon and Gabon. AIDS 1993; 7: 1536-8.
6. Gurtler LG, Hauser PH, Eberle J, et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994 ; 68 : 1581-5.
7. Charneau P, Borman AM, Quillent C, et al. Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology 1994 ; 205 : 247-53.
8. Vanden Haesevelde M, Decourt JL, De Leys RJ, et al. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol 1994 ; 68 : 1586-96.
9. Simon F, Mauclere P, Roques P, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998 ; 4 : 1032-7.
10. Plantier JC, Leoz M, Dickerson JE, et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009 ; 15 : 871-2.
11. Van Heuverswyn F, Li Y, Neel C, et al. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006 ; 444 : 164.
12. Vallari A, Yamaguchi J, Holzmayer V, et al. HIV-1 group P: confirmation of group P in Cameroon. In: 17th Conference on retroviruses and opportunistic infections. San Francisco, États-Unis. 2010.
13. Huet T, Cheynier R, Meyerhans A, Roelants G, Wain-Hobson S. Genetic organization of a chimpanzee lentivirus related to HIV-1. Nature 1990 ; 345 : 356-9. (Pubitemid 120028884)
14. Peeters M, Honore C, Huet T, et al. Isolation and partial characterization of an HIV-related virus occurring naturally in chimpanzees in Gabon. AIDS 1989 ; 3 : 625-30.
15. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee pan troglodytes troglodytes. Nature 1999 ; 397 : 436-41.
16. Hahn B, Shaw GM, De Cock K, Sharp PM. AIDS as a zoonosis: scientific and public health implications. Science 2000 ; 287 : 607-14.
17. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006 ; 313 : 523-6.
18. Van Heuverswyn F, Li Y, Bailes E, et al. Genetic diversity and phylogeographic clustering of SIVcpzPtt in wild chimpanzees in Cameroon. Virology 2007 ; 368 : 155-71.
19. Worobey M, Gemmel M, Teuwen DE, et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008 ; 455 : 661-4.
20. Lemey P, Pybus OG, Rambaut A, et al. The molecular population genetics of HIV-1 group O. Genetics 2004 ; 167 : 1059-68.
21. Wertheim JO, Worobey M. Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2. PLoS Comput Biol 2009 ; 5 : e1000377.
22. Jonassen TO, Stene-Johansen K, Berg ES, et al. Sequence analysis of HIV-1 group O from Norwegian patients infected in the 1960s. Virology 1997 ; 231 : 43-7. (Pubitemid 27238760)
23. Wain LV, Bailes E, Bibollet-Ruche F, et al. Adaptation of HIV-1 to its human host. Mol Biol Evol 2007 ; 24 : 1853-60.
24. Takehisa J, Kraus MH, Ayouba A, et al. Origin and biology of simian immunodeficiency virus in wild-living western gorillas. J Virol 2009 ; 83 : 1635-48.
25. Sauter D, Schindler M, Specht A, et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009 ; 6 : 409-21.
26. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005 ; 79 : 8979-90.
27. Archer J, Robertson DL. Understanding the diversification of HIV-1 groups M and O. AIDS 2007 ; 21 : 1693-700.
28. Roques P, Robertson DL, Souquiere S, et al. Phylogenetic analysis of 49 newly derived HIV-1 group O strains: high viral diversity but no group M-like subtype structure. Virology 2002 ; 302 : 259-73.
29. Yamaguchi J, Vallari AS, Swanson P, et al. Evaluation of HIV type 1 group O isolates: identification of five phylogenetic clusters. AIDS Res Hum Retroviruses 2002 ; 18 : 269-82.
30. Vallari A, Bodelle P, Ngansop C, et al. Four new HIV-1 group N isolates from Cameroon: Prevalence continues to be low. AIDS Res Hum Retroviruses 2010 ; 26 : 109-15.
31. Roques P, Robertson DL, Souquiere S, et al. Phylogenetic characteristics of three new HIV-1 N strains and implications for the origin of group N. AIDS 2004 ; 18 : 1371-81.
32. Dittmar MT, Zekeng L, Kaptue L, Eberle J, Krausslich HG, Gurtler L. Coreceptor requirements of primary HIV type 1 group O isolates from Cameroon. AIDS Res Hum Retroviruses 1999 ; 15 : 707-12. (Pubitemid 29237393)
33. Braaten D, Franke EK, Luban J. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J Virol 1996 ; 70 : 4220-7.
34. Wiegers K, Krausslich HG. Differential dependence of the infectivity of HIV-1 group O isolates on the cellular protein cyclophilin A. Virology 2002 ; 294 : 289-95.
35. Vallejo A, Gurtler L, Zekeng L, Hewlett IK. Nucleotide sequence analysis of the accessory genes of HIV-1 group O isolates. Virus Res 2003 ; 91 : 189-93. (Pubitemid 36165087)
36. Bibollet-Ruche F, Loussert-Ajaka I, Simon F, et al. Genetic characterization of accessory genes from human immunodeficiency virus type 1 group O strains. AIDS Res Hum Retroviruses 1998 ; 14 : 951-61.
37. Bilodeau PS, Domsic JK, Stoltzfus CM. Splicing regulatory elements within tat exon 2 of human immunodeficiency virus type 1 (HIV-1) are characteristic of group M but not group O HIV-1 strains. J Virol 1999 ; 73 : 9764-72.
38. Quinones-Mateu ME, Soriano V, Domingo E, Menendez-Arias L. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. Virology 1997 ; 236 : 364-73.
39. Menendez-Arias L, Abraha A, Quinones-Mateu ME, Mas A, Camarasa MJ, Arts EJ. Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains. J Biol Chem 2001 ; 276 : 27470-9.
40. Alvarez M, Matamoros T, Menendez-Arias L. Increased thermostability and fidelity of DNA synthesis of wild-type and mutant HIV-1 group O reverse transcriptases. J Mol Biol 2009 ; 392 : 872-84.
41. Depatureaux A, Leoz M, De Oliveira F, et al. Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data. Med Mal Infect 2010: doi:10.1016/j.medmal.2010.04.011.
42. Nkengasong JN, Fransen K, Willems B, et al. Virologic, immunologic, and clinical follow-up of a couple infected by the human immunodeficiency virus type one, group O. J Med Virol 1997 ; 51 : 202-9.
43. Andreoletti L, Reveil B, Moret H, et al. Significant genetic and antigenic variability within the env gene of systemic human immunodeficiency virus type 1 group O populations during the natural course of a heterosexual infection: a pilot study. J Clin Microbiol 2007 ; 45 : 1319-21.
44. Geuenich S, Kaderali L, Allespach I, Sertel S, Keppler OT. Biological signature characteristics of primary isolates from human immunodeficiency virus type 1 group O in ex vivo human tonsil histocultures. J Virol 2009 ; 83 : 10494-503.
45. Vessiere A, Rousset D, Kfutwah A, et al. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J Acquir Immune Defic Syndr 2010 ; 53 : 107-10.
46. Gueudin M, Lemee V, Ferre V, et al. Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O. J Acquir Immune Defic Syndr 2004 ; 36 : 639-41.
47. Chaix-Baudier ML, Chappey C, Burgard M, et al. First case of mother-to-infant HIV type 1 group O transmission and evolution of C2V3 sequences in the infected child. French HIV Pediatric Cohort Study Group. AIDS Res Hum Retroviruses 1998 ; 14 : 15-23.
48. Ayouba A, Souquieres S, Njinku B, et al. HIV-1 group N among HIV-1-seropositive individuals in Cameroon. AIDS 2000 ; 14 : 2623-5.
49. Yamaguchi J, Coffey R, Vallari A, et al. Identification of HIV type 1 group N infections in a husband and wife in Cameroon: viral genome sequences provide evidence for horizontal transmission. AIDS Res Hum Retroviruses 2006 ; 22 : 83-92.
50. Yamaguchi J, McArthur CP, Vallari A, et al. HIV-1 group N: evidence of ongoing transmission in Cameroon. AIDS Res Hum Retroviruses 2006 ; 22 : 453-7.
51. Ayouba A, Mauclere P, Martin PM, et al. HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg Infect Dis 2001 ; 7 : 466-7.
52. Vergne L, Bourgeois A, Mpoudi-Ngole E, et al. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02-AG variant and disease stage. Virology 2003 ; 310 : 254-66.
53. Yamaguchi BP, Vallari AS, Coffey R, et al. HIV infections in northwestern Cameroon: identification of HIV type 1 group O and dual HIV type 1 group M and group O infections. AIDS Research and human retroviruses 2004 ; 20 : 944-55.
54. Takehisa J, Zekeng L, Ido E, et al. Human immunodeficiency virus type 1 intergroup (M/O) recombination in Cameroon. J Virol 1999 ; 73 : 6810-20.
55. Peeters M, Liegeois F, Torimiro N, et al. Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient. J Virol 1999 ; 73 : 7368-75.
56. Barin F, Cazein F, Lot F, et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS 2007 ; 21 : 2351-3.
57. Brand D, Beby-Defaux A, Mace M, et al. First identification of HIV-1 groups M and O dual infections in Europe. AIDS 2004 ; 18 : 2425-8.
58. Plantier JC, Lemee V, Dorval I, et al. HIV-1 group M superinfection in an HIV-1 group O-infected patient. AIDS 2004 ; 18 : 2444-6.
59. Vessiere A, Leoz M, Brodard V, et al. First evidence of a HIV-1 M/O recombinant form circulating outside Cameroon. AIDS 2010 ; 24 : 1079-82.
60. Loussert-Ajaka I, Ly TD, Chaix ML, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994 ; 343 : 1393-4.
61. Simon F, Ly TD, Baillou-Beaufils A, et al. Sensitivity of screening kits for anti-HIV-1 subtype O antibodies. AIDS 1994 ; 8 : 1628-9.
62. Ly TD, Laperche S, Brennan C, et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods 2004 ; 122 : 185-94.
63. Zouhair S, Roussin-Bretagne S, Moreau A, et al. Group o human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays. J Clin Microbiol 2006 ; 44 : 662-5.
64. Henquell C, Jacomet C, Antoniotti O, et al. Difficulties in diagnosing group o human immunodeficiency virus type 1 acute primary infection. J Clin Microbiol 2008 ; 46 : 2453-6.
65. Gautheret-Dejean A, Mesmin-Poho S, Birguel J, Lemee V, Huraux JM, Plantier JC. Unequal detection of HIV type 1 group O infection by simple rapid tests. Clin Infect Dis 2008 ; 46 : 1936-7.
66. Plantier JC, Djemai M, Lemee V, et al. Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections. J Clin Microbiol 2009 ; 47 : 2906-11.
67. Gueudin M, Plantier JC, Damond F, Roques P, Mauclere P, Simon F. Plasma viral RNA assay in HIV-1 group O infection by real-time PCR. J Virol Methods 2003 ; 113 : 43-9.
68. Plantier JC, Gueudin M, Damond F, Braun J, Mauclere P, Simon F. Plasma RNA quantification and HIV-1 divergent strains. J Acquir Immune Defic Syndr 2003 ; 33 : 1-7. (Pubitemid 36547234)
69. Delaugerre C, Merzoug M, Plantier JC, et al. Evaluation of extraction-quantification systems COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, version 2.0 vs M2000SP/Abbott RealTime® HIV-1 in HIV-1 group M Subtypes B and Non-B, group O, and group P samples. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, États-Unis. 2010.
70. Tang N, Huang S, Salituro J, et al. A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods 2007 ; 146 : 236-45.
71. Tuaillon E, Gueudin M, Lemee V, et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 2004 ; 37 : 1543-9.
72. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997 ; 71 : 8893-8.
73. Luk KC, Kaptue L, Zekeng L, et al. Naturally occurring sequence polymorphisms within HIV type 1 group O protease. AIDS Res Hum Retroviruses 2001 ; 17 : 1555-61.
74. Leoz M, Depatureaux A, Vessiere A, et al. Integrase polymorphism and HIV-1 group O diversity. AIDS 2008 ; 22 : 1239-43.
75. Briz V, Garrido C, Poveda E, et al. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses 2009 ; 25 : 225-7.
76. Depatureaux A, Charpentier C, Collin G, et al. Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 group O to enfuvirtide. Antimicrob Agents Chemother 2010 ; 54 : 4016-9.
77. Chinnadurai R, Munch J, Dittmar MT, Kirchhoff F. Inhibition of HIV-1 group M and O isolates by fusion inhibitors. AIDS 2005 ; 19 : 1919-22.
78. Poveda E, Barreiro P, Rodes B, Soriano V. Enfuvirtide is active against HIV type 1 group O. AIDS Res Hum Retroviruses 2005 ; 21 : 583-5.
79. Rupp D, Geuenich S, Keppler OT. Poor performance of bioinformatics programs for genotypic prediction of coreceptor usage of HIV-1 group o isolates. J Acquir Immune Defic Syndr 2010 ; 53 : 412-3.
80. de Baar MP, Janssens W, de Ronde A, et al. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. AIDS Res Hum Retroviruses 2000 ; 16 : 1385-94.
81. Rodes B, de Mendoza C, Rodgers M, et al. Treatment response and drug resistance in patients infected with HIV type 1 group O viruses. AIDS Res Hum Retroviruses 2005 ; 21 : 602-7.